In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
A pathway to recovery
An opinion article from ICON's Chief Medical Officer, Kristen Buck on the role of Chief Medical Officers.
-
Treatment options for Clostridioides difficile
This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. Samedan Ltd.
-
A golden opportunity… but not a silver bullet
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked.
-
Decentralised trials – aided by tech – could boost clinical research
A Pharmaphorum article which considers how bringing clinical trials to patients – rather than the reverse – could be the key to improving recruitment into studies and making them faster, cheaper and more likely to succeed.
-
Adapting for the future of oncology
ICON experts Andreas Dreps and Martin Lachs share their thoughts on the future of cancer research and the importance of staying adaptive in PharmaPhorum's 'Future of Oncology 2020' magazine.
-
Navigating complexity in oncology cell and gene therapy clinical trials
This article featured in ClinicalOmics 'Insider's guide to precision medicine 2020' (pages 48 & 49) considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
-
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
-
The potential of activity trackers to bias study results
A thought leadership article authored by Marie McCarthy, Tim Clark and Peter Schueler on the impact of activity trackers on study participants and study endpoints.
-
A conversation with an expert in drug development
Colin Orford, Senior Vice President of Drug Development services at ICON, about finding an effective treatment for COVID-19.
